This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Nefiracetam
- DrugBank Accession Number
- DB13082
- Background
Nefiracetam has been used in trials studying the treatment of Alzheimer's Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Nefiracetam (DB13082)
- Weight
- Average: 246.31
Monoisotopic: 246.136827828 - Chemical Formula
- C14H18N2O2
- Synonyms
- Nefiracetam
- Nefiracetamum
- External IDs
- DM 9384
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Nefiracetam. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Nefiracetam. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Nefiracetam. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Nefiracetam. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Nefiracetam. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Nefiracetam. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Nefiracetam. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Nefiracetam. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Nefiracetam. Alverine The risk or severity of adverse effects can be increased when Alverine is combined with Nefiracetam. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids and derivatives
- Alternative Parents
- Anilides / m-Xylenes / N-arylamides / Pyrrolidine-2-ones / N-alkylpyrrolidines / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds show 3 more
- Substituents
- 2-pyrrolidone / Alpha-amino acid or derivatives / Anilide / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Hydrocarbon derivative / Lactam show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1JK12GX30N
- CAS number
- 77191-36-7
- InChI Key
- NGHTXZCKLWZPGK-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
- IUPAC Name
- N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
- SMILES
- CC1=CC=CC(C)=C1NC(=O)CN1CCCC1=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 71157
- PubChem Substance
- 347829207
- ChemSpider
- 64299
- ChEBI
- 135004
- ChEMBL
- CHEMBL260829
- ZINC
- ZINC000000003788
- Wikipedia
- Nefiracetam
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Alzheimer's Disease (AD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.704 mg/mL ALOGPS logP 1.62 ALOGPS logP 1.58 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 13.75 Chemaxon pKa (Strongest Basic) -2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 49.41 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 71.6 m3·mol-1 Chemaxon Polarizability 26.6 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-004j-7920010011-f3cb0b77efee19ef8d89
Drug created at October 21, 2016 02:49 / Updated at February 21, 2021 18:54